Skip to main content
main-content
Erschienen in: NeuroTransmitter 3/2022

09.03.2022 | Morbus Alzheimer | Zertifizierte Fortbildung

Prodromale Stadienkonzepte der neurodegenerativen Demenzen

Von symptombasierter Diagnostik hin zu einem biologischen Konzept

verfasst von: MD Dr. med. Julia Bungenberg, PhD Dr. Ana Sofia Costa, Prof. Dr. med. Kathrin Reetz

Erschienen in: NeuroTransmitter | Ausgabe 3/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Das Interesse Frühstadien bei neurodegenerativen Erkrankungen wie der Alzheimer-Krankheit, der frontotemporalen Demenz, der Lewy-Körperchen-Krankheit und der Parkinson-Krankheit zu detektieren ist groß, denn pathophysiologische Veränderungen im Gehirn treten meist schon Jahrzehnte vor Symptombeginn auf und bergen daher erhebliches krankheitsmodifizierendes Potenzial. Mit neuen Biomarkern ist es heute aber bereits zunehmend möglich, Personen in einem präklinischen oder prodromalen Stadium neurodegenerativer Erkrankungen zu identifizieren. …
Literatur
1.
Zurück zum Zitat Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58(12):1791-800 Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58(12):1791-800
2.
Zurück zum Zitat Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 1997;9 Suppl 1:257-61; discussion 69-72 Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 1997;9 Suppl 1:257-61; discussion 69-72
3.
Zurück zum Zitat Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25(34):7709-17 Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25(34):7709-17
4.
Zurück zum Zitat Jack CR et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12(2):207-16 Jack CR et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12(2):207-16
5.
Zurück zum Zitat Jack CR et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68(12):1526-35 Jack CR et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68(12):1526-35
6.
Zurück zum Zitat Vermunt L et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimers Dement 2019;15(7):888-98 Vermunt L et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimers Dement 2019;15(7):888-98
7.
Zurück zum Zitat Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-9 Albert MS et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-9
8.
Zurück zum Zitat Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69(1):181-92 Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011;69(1):181-92
9.
Zurück zum Zitat Resnick SM et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74(10):807-15 Resnick SM et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74(10):807-15
10.
Zurück zum Zitat Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12(3):292-323 Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12(3):292-323
11.
Zurück zum Zitat McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-9 McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-9
12.
Zurück zum Zitat Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87(5):539-47 Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 2016;87(5):539-47
13.
Zurück zum Zitat Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131(Pt 6):1630-45 Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131(Pt 6):1630-45
14.
Zurück zum Zitat Blennow K, Mattsson N, Scholl M et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36(5):297-309 Blennow K, Mattsson N, Scholl M et al. Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci 2015;36(5):297-309
15.
Zurück zum Zitat Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology 2019;92(6):e601-e12 Ossenkoppele R, Smith R, Ohlsson T, Strandberg O, Mattsson N, Insel PS et al. Associations between tau, Abeta, and cortical thickness with cognition in Alzheimer disease. Neurology 2019;92(6):e601-e12
16.
Zurück zum Zitat Simren J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol 2020;61:29-39 Simren J, Ashton NJ, Blennow K, Zetterberg H. An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. Curr Opin Neurobiol 2020;61:29-39
17.
Zurück zum Zitat Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14(4):535-62 Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14(4):535-62
18.
Zurück zum Zitat Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Jr., Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021 Sep;17(9):580-9 Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Jr., Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 2021 Sep;17(9):580-9
19.
Zurück zum Zitat Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456-77 Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456-77
20.
Zurück zum Zitat Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006-14 Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76(11):1006-14
21.
Zurück zum Zitat Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011;82(5):476-86 Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011;82(5):476-86
22.
Zurück zum Zitat Tavares TP, Mitchell DGV, Coleman KK, Coleman BL, Shoesmith CL, Butler CR, et al. Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2020;91(9):975-84 Tavares TP, Mitchell DGV, Coleman KK, Coleman BL, Shoesmith CL, Butler CR, et al. Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2020;91(9):975-84
23.
Zurück zum Zitat Korhonen T, Katisko K, Cajanus A, Hartikainen P, Koivisto AM, Haapasalo A et al. Comparison of Prodromal Symptoms of Patients with Behavioral Variant Frontotemporal Dementia and Alzheimer Disease. Dement Geriatr Cogn Disord 2020;49(1):98-106 Korhonen T, Katisko K, Cajanus A, Hartikainen P, Koivisto AM, Haapasalo A et al. Comparison of Prodromal Symptoms of Patients with Behavioral Variant Frontotemporal Dementia and Alzheimer Disease. Dement Geriatr Cogn Disord 2020;49(1):98-106
24.
Zurück zum Zitat Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 2017;13(7):406-19 Meeter LH, Kaat LD, Rohrer JD, van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nat Rev Neurol 2017;13(7):406-19
25.
Zurück zum Zitat Foiani MS, Cicognola C, Ermann N, Woollacott IOC, Heller C, Heslegrave AJ et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. J Neurol Neurosurg Psychiatry 2019;90(7):740-6 Foiani MS, Cicognola C, Ermann N, Woollacott IOC, Heller C, Heslegrave AJ et al. Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. J Neurol Neurosurg Psychiatry 2019;90(7):740-6
26.
Zurück zum Zitat Zhang JV, Irwin DJ, Blennow K, Zetterberg H, Lee EB, Shaw LM et al. Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurol Clin Pract 2021;11(2):105-16 Zhang JV, Irwin DJ, Blennow K, Zetterberg H, Lee EB, Shaw LM et al. Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurol Clin Pract 2021;11(2):105-16
27.
Zurück zum Zitat Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S et al. Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain 2019;142(1):193-208 Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S et al. Longitudinal multimodal MRI as prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. Brain 2019;142(1):193-208
28.
Zurück zum Zitat Tavares TP, Mitchell DGV, Coleman K, Shoesmith C, Bartha R, Cash DM et al. Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology 2019;93(18):e1699-e706 Tavares TP, Mitchell DGV, Coleman K, Shoesmith C, Bartha R, Cash DM et al. Ventricular volume expansion in presymptomatic genetic frontotemporal dementia. Neurology 2019;93(18):e1699-e706
29.
Zurück zum Zitat De Vocht J, Blommaert J, Devrome M, Radwan A, Van Weehaeghe D, De Schaepdryver M, et al. Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurol 2020;77(8):1008-17 De Vocht J, Blommaert J, Devrome M, Radwan A, Van Weehaeghe D, De Schaepdryver M, et al. Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of C9orf72 Repeat Expansion. JAMA Neurol 2020;77(8):1008-17
30.
Zurück zum Zitat Popuri K, Beg MF, Lee H et al. FDG-PET in presymptomatic C9orf72 mutation carriers. Neuroimage Clin 2021;31:102687 Popuri K, Beg MF, Lee H et al. FDG-PET in presymptomatic C9orf72 mutation carriers. Neuroimage Clin 2021;31:102687
31.
Zurück zum Zitat McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88-100 McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88-100
32.
Zurück zum Zitat McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020;94(17):743-55 McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 2020;94(17):743-55
33.
Zurück zum Zitat Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18(2):101-13 Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci 2017;18(2):101-13
34.
Zurück zum Zitat Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019;34(10):1464-70 Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord 2019;34(10):1464-70
35.
Zurück zum Zitat Iranzo A, Stefani A, Serradell M, Marti MJ, Lomena F, Mahlknecht P et al. Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 2017;89(3):242-8 Iranzo A, Stefani A, Serradell M, Marti MJ, Lomena F, Mahlknecht P et al. Characterization of patients with longstanding idiopathic REM sleep behavior disorder. Neurology 2017;89(3):242-8
36.
Zurück zum Zitat Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12(5):443-53 Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12(5):443-53
37.
Zurück zum Zitat Heinzel S, Kasten M, Behnke S, Vollstedt EJ, Klein C, Hagenah J et al. Age- and sex-related heterogeneity in prodromal Parkinson's disease. Mov Disord 2018;33(6):1025-7 Heinzel S, Kasten M, Behnke S, Vollstedt EJ, Klein C, Hagenah J et al. Age- and sex-related heterogeneity in prodromal Parkinson's disease. Mov Disord 2018;33(6):1025-7
38.
Zurück zum Zitat Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 2021;20(8):671-84 Miglis MG, Adler CH, Antelmi E, Arnaldi D, Baldelli L, Boeve BF et al. Biomarkers of conversion to alpha-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurol 2021;20(8):671-84
39.
Zurück zum Zitat Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol 2021;17(6):349-61 Berg D, Borghammer P, Fereshtehnejad SM, Heinzel S, Horsager J, Schaeffer E et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol 2021;17(6):349-61
Metadaten
Titel
Prodromale Stadienkonzepte der neurodegenerativen Demenzen
Von symptombasierter Diagnostik hin zu einem biologischen Konzept
verfasst von
MD Dr. med. Julia Bungenberg
PhD Dr. Ana Sofia Costa
Prof. Dr. med. Kathrin Reetz
Publikationsdatum
09.03.2022
Verlag
Springer Medizin
Erschienen in
NeuroTransmitter / Ausgabe 3/2022
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI
https://doi.org/10.1007/s15016-022-9371-2

Weitere Artikel der Ausgabe 3/2022

NeuroTransmitter 3/2022 Zur Ausgabe